Neuroprotective Agents - Administration & dosage
Research News and Information

Monday, November 23, 2009

A double-blind, delayed-start trial of rasagiline in Parkinson's disease.

22 Sep 2009 BACKGROUND: A therapy that slows disease progression is the major unmet need in Parkinson's disease. METHODS: In this double-blind trial, we examined the possibility that rasagiline has disease-modifying effects in Parkinson's disease. A total of ... Read more...

[Effects of piracetam therapy in a case of Lance-Adams syndrome]

30 Aug 2009 We report a 17-year-old female patient with Lance-Adams syndrome caused by anoxic encephalopathy during a severe attack of bronchial asthma. She had difficulty in writing because of action myoclonus in her arms. She also exhibited freezing gait and ... Read more...

Neuroprotection in a 6-hydroxydopamine-lesioned Parkinson model using lactoferrin-modified nanoparticles.

30 Aug 2009 BACKGROUND: Nonviral gene therapy of chronic degenerative diseases such as Parkinson's disease (PD) is a great challenge as a result of the low tranfection efficiency of nonviral gene vectors. We previously constructed a lactoferrin (Lf)-modified ... Read more...

Latest indexed articles for 'Neuroprotective Agents - Administration & dosage'

These are the very latest articles for this heading:

• A double-blind, delayed-start trial of rasagiline in Parkinson's disease. 22 Sep 2009
• [Effects of piracetam therapy in a case of Lance-Adams syndrome] 30 Aug 2009
• Neuroprotection in a 6-hydroxydopamine-lesioned Parkinson model using lactoferrin-modified nanoparticles. 30 Aug 2009
• Central administration of minocycline and riluzole prevents morphine-induced tolerance in rats. 30 Aug 2009
• Asiatic acid, a pentacyclic triterpene from Centella asiatica, is neuroprotective in a mouse model of focal cerebral ischemia. 13 Aug 2009
• Systemic lipopolysaccharide protects the brain from ischemic injury by reprogramming the response of the brain to stroke: a critical role for IRF3. 3 Aug 2009
• Cost-effectiveness of ziconotide in intrathecal pain management for severe chronic pain patients in the UK. 30 Jul 2009
• A safety and tolerability laboratory study of the combination of aripiprazole and topiramate in volunteers who drink alcohol. 30 Jul 2009
• Rivastigmine in Parkinson's disease dementia. 30 Jul 2009
• Effect of intrathecal FK506 administration on intraorbital optic nerve crush: an ultrastructural study. 30 Jul 2009
• A closed-circuit neonatal xenon delivery system: a technical and practical neuroprotection feasibility study in newborn pigs. 30 Jul 2009
• Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease. 27 Jul 2009
• Systemic administration of an antagonist of the ATP-sensitive receptor P2X7 improves recovery after spinal cord injury. 25 Jul 2009
• Oral administration of coenzyme Q(10) prevents cytochrome c release from mitochondria induced by 1-methyl-4-phenylpyridinium ion in mouse brain synaptosomes. 24 Jul 2009
• Rutin protects the neural damage induced by transient focal ischemia in rats. 20 Jul 2009
• Delta opioid agonist [D-Ala2, D-Leu5] enkephalin (DADLE) reduced oxygen-glucose deprivation caused neuronal injury through the MAPK pathway. 16 Jul 2009
• Protection of DFP-induced oxidative damage and neurodegeneration by antioxidants and NMDA receptor antagonist. 12 Jul 2009
• Effect of Hibiscus rosa sinensis on reserpine-induced neurobehavioral and biochemical alterations in rats. 29 Jun 2009
• Injury and repair mechanisms in ischemic stroke: considerations for the development of novel neurotherapeutics. 29 Jun 2009
• Cyclosporine A for neuroprotection: establishing dosing guidelines for safe and effective use. 29 Jun 2009

See a longer list of these articles.

Technical information about 'Neuroprotective Agents'

Definition: Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids.

Registry Number: 0

Descriptor UI: D018696

Alternative terms: Neuroprotective Agents; Agents, Neuroprotective; Neuroprotectants; Neuroprotective Drugs; Drugs, Neuroprotective;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.696.706.548; D27.505.954.427.575;

History Note: 95

Technical Notes: GEN or unspecified; prefer specifics; prevent brain & spinal cord damage in neurol dis